In this issue, we present another installment of our quarterly review of dealmaking—for July-September 2002. Our data comes from Windhover's Strategic Transactions Database , which covers deal activi
It's been a big quarter for organizational changes at the US Food and Drug Administration: a new candidate for Commissioner, the consolidation of some CBER functions into CDER ( see "A New Commissione
To be sure, over the years, a handful of companies have taken potshots at Roche Molecular Systems Inc. , the molecular diagnostics subsidiary of Roche . But RMS maintains a powerful presence, wi
Debate about getting the FDA involved in regulating home brews has the lab and IVD industries on edge. Would agency oversight help get more FDA-cleared genetic tests on the market? by Wendy Diller It'